AI-generated summary
This review examines how transcranial photobiomodulation, which delivers near-infrared and infrared light through the scalp to the brain, may act at the molecular level to address cognitive decline. The authors also propose applying this approach to dogs with canine cognitive dysfunction, a condition they describe as a naturally occurring model of Alzheimer's disease. The abstract notes that cognitive improvement has been documented in rodent Alzheimer's models and human clinical trials, but it does not report any new experimental results from this review.
- Who or what was studied
- Review of rodent Alzheimer's models, human clinical trials and dogs with canine cognitive dysfunction (no specific numbers stated)
- Limits stated in the abstract
- The abstract describes a review and proposal without reporting a specific number of studies, participants or outcome measures.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ejmanager.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Laser, Photobiomodulation therapy, Cognitive decline. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.